Extended Data Fig. 6: Lenvatinib plus EGFR inhibitors suppresses the ERK1/2 MAPK pathway in EGFRhigh liver cancer cells. | Nature

Extended Data Fig. 6: Lenvatinib plus EGFR inhibitors suppresses the ERK1/2 MAPK pathway in EGFRhigh liver cancer cells.

From: EGFR activation limits the response of liver cancer to lenvatinib

Extended Data Fig. 6

af, Immunoblot and quantification of p-EGFR and p-ERK1/2 levels in liver cancer cells after the indicated treatment. EGFRhigh and EGFRlow liver cancer cell lines were treated with lenvatinib, EGFR inhibitors (gefitinib or erlotinib) or their combination at the indicated concentrations for 24 h. Protein extracts were probed with specific antibodies against EGFR (total and phosphorylated), ERK1/2 (total and phosphorylated) and HSP90 (as a loading control). Data are mean ± s.e.m., n = 3 independent experiments. P values were determined by two-sided unpaired Student’s t-test. gj, Liver cancer cell lines SNU449 (g), JHH1 (h), Huh6 (i) and SNU182 (j) were treated with DMSO, lenvatinib, gefitinib or the combination of both drugs for 24 h. The mRNA levels of 10 transcriptional targets of MAPK signalling (DUSP4, DUSP6, ETV4, ETV5, EPHA2, EPHA4, SPRY2, SPRY4, PHLDA1 and CCND1) were determined by RT–qPCR analysis. ACTB (which encodes β-actin) was used as internal control. Data are mean ± s.e.m. (n = 3)

Source data.

Back to article page